LX4211

DRUG3 trials

Sponsors

Lexicon Pharmaceuticals

Conditions

HealthyRenal ImpairmentType 2 Diabetes Mellitus

Phase 1

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

CompletedNCT01441232

Lexicon PharmaceuticalsType 2 Diabetes Mellitus

Start: 2011-10-31Updated: 2012-01-31

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

CompletedNCT01555008

Lexicon PharmaceuticalsRenal Impairment, Type 2 Diabetes Mellitus

Start: 2012-03-31Updated: 2013-09-09

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

CompletedNCT02373046

Lexicon PharmaceuticalsHealthy

Start: 2015-02-28Updated: 2015-10-02

Related Papers

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.

2019-02-28120 citations

LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.

2014-12-1736 citations

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.

2013-02-2162 citations